Huihua Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huihua Zhang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Qianting Yang
National Clinical Research Center for Infectious Diseases, Guangdong Key Lab for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China
4 shared publications- Youchao Dai
Guangzhou Medical Research Institute of Infectious Diseases, Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University
4 shared publications Jiang Zeng
Department of Clinical Laboratory, Ganzhou Fifth People's Hospital, The Ninth Affiliated Clinical College of Gannan Medical University, Ganzhou, People's Republic of China
3 shared publicationsQi Chen
3 shared publicationsXinchun Chen
3 shared publications- Xinchun Chen
Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, Shenzhen University Medical School
3 shared publications
Latest Publications
Plasma miRNA signature for the diagnosis of pulmonary tuberculosis in symptomatic patients
Background: The prompt and precise diagnosis of active pulmonary tuberculosis (TB) is crucial for controlling this disease and yet it remains a global challenge. The objective of this study was to identify a set of microRNAs (miRNAs) whose expression in plasma could be used as a triage test for diagnosing TB. Methods: A total of 879 plasma samples were collected in seven clinical centres from healthy individuals and patients displaying TB-like symptoms and/or radiological features consistent with TB. The samples were classified as TB, pneumonia, lung cancer and HC subgroups based on subsequent diagnostic assessments. We performed quantitative profiling of 264 plasma miRNAs in a training cohort (n=410) and an independent external test cohort (n=469). After dimensionality reduction and feature selection analysis, we identified nine discriminative miRNAs and used them to train an ensemble model in a training cohort using the scikit-learn library, which was subsequently evaluated in the external test cohort. Results: The ensemble model showed notable accuracy in discriminating TB from non-TB patients, yielding areas under the curve (AUC) of 0.84 (95% CI 0.80 to 0.88) for the training cohort and 0.86 (95% CI 0.82 to 0.90) for the external test cohort. When tested against subgroups of laboratory confirmed and clinically diagnosed but unconfirmed TB, the AUC values were 0.89 (95% CI 0.85 to 0.93) and 0.83 (95% CI 0.79 to 0.88), respectively. In smear-negative confirmed TB patients, the AUC exceeded 0.83, with a sensitivity and specificity of 0.75. Conclusions: Our miRNA ensemble model, based on detecting a nine-miRNA expression biosignature in plasma, demonstrated promising ability to diagnose TB and distinguish it from other common lung diseases but further studies are needed to assess its clinical applicability. Trial registration number: ChiCTR2000039734.
Plasma miRNA signature for the diagnosis of pulmonary tuberculosis in symptomatic patients
Background: The prompt and precise diagnosis of active pulmonary tuberculosis (TB) is crucial for controlling this disease and yet it remains a global challenge. The objective of this study was to identify a set of microRNAs (miRNAs) whose expression in plasma could be used as a triage test for diagnosing TB. Methods: A total of 879 plasma samples were collected in seven clinical centres from healthy individuals and patients displaying TB-like symptoms and/or radiological features consistent with TB. The samples were classified as TB, pneumonia, lung cancer and HC subgroups based on subsequent diagnostic assessments. We performed quantitative profiling of 264 plasma miRNAs in a training cohort (n=410) and an independent external test cohort (n=469). After dimensionality reduction and feature selection analysis, we identified nine discriminative miRNAs and used them to train an ensemble model in a training cohort using the scikit-learn library, which was subsequently evaluated in the external test cohort. Results: The ensemble model showed notable accuracy in discriminating TB from non-TB patients, yielding areas under the curve (AUC) of 0.84 (95% CI 0.80 to 0.88) for the training cohort and 0.86 (95% CI 0.82 to 0.90) for the external test cohort. When tested against subgroups of laboratory confirmed and clinically diagnosed but unconfirmed TB, the AUC values were 0.89 (95% CI 0.85 to 0.93) and 0.83 (95% CI 0.79 to 0.88), respectively. In smear-negative confirmed TB patients, the AUC exceeded 0.83, with a sensitivity and specificity of 0.75. Conclusions: Our miRNA ensemble model, based on detecting a nine-miRNA expression biosignature in plasma, demonstrated promising ability to diagnose TB and distinguish it from other common lung diseases but further studies are needed to assess its clinical applicability. Trial registration number: ChiCTR2000039734.
- Open Access
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Landscape of Immune Cell–Type–Specific Transcriptomic and Splicing Regulation in Tuberculosis Revealed by Smart Sequencing
Understanding how immune cell programs diverge between active tuberculosis (TB) and latent tuberculosis infection (LTB) is essential for improving diagnosis and treatment. Here, we performed a large-scale, full-length, splicing-resolved transcriptomic analysis across 16 purified immune cell types using mini-bulk RNA sequencing. The dataset comprised 2,578 profiles from 43 TB patients, 11 individuals with LTB, and 31 healthy controls, together with longitudinal follow-up data from 10 TB patients during treatment. Analysis of immune cell composition identified increased frequencies of granulocytes, intermediate monocytes, Th17 cells, and regulatory T cells in active TB compared with healthy controls. Beyond cellular composition, alternative splicing (AS) emerged as a major regulatory layer, with T cell subsets exhibiting extensive splicing alterations both during disease and following treatment. Distinct cell-type-specific splicing signatures differentiated TB from LTB, including differential isoform usage of IFNGR1, guanylate-binding proteins, caspases, and gasdermin D along interferon-γ and cell-death-related pathways. These splicing alterations were partially reversed during anti-TB treatment, indicating dynamic regulation linked to disease state. Together, this study defines a splicing-resolved, cell-type-specific immune landscape of TB and reveals AS as a key regulatory mechanism shaping immune dysfunction and recovery during infection and treatment immune.
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLandscape of Immune Cell–Type–Specific Transcriptomic and Splicing Regulation in Tuberculosis Revealed by Smart Sequencing
Understanding how immune cell programs diverge between active tuberculosis (TB) and latent tuberculosis infection (LTB) is essential for improving diagnosis and treatment. Here, we performed a large-scale, full-length, splicing-resolved transcriptomic analysis across 16 purified immune cell types using mini-bulk RNA sequencing. The dataset comprised 2,578 profiles from 43 TB patients, 11 individuals with LTB, and 31 healthy controls, together with longitudinal follow-up data from 10 TB patients during treatment. Analysis of immune cell composition identified increased frequencies of granulocytes, intermediate monocytes, Th17 cells, and regulatory T cells in active TB compared with healthy controls. Beyond cellular composition, alternative splicing (AS) emerged as a major regulatory layer, with T cell subsets exhibiting extensive splicing alterations both during disease and following treatment. Distinct cell-type-specific splicing signatures differentiated TB from LTB, including differential isoform usage of IFNGR1, guanylate-binding proteins, caspases, and gasdermin D along interferon-γ and cell-death-related pathways. These splicing alterations were partially reversed during anti-TB treatment, indicating dynamic regulation linked to disease state. Together, this study defines a splicing-resolved, cell-type-specific immune landscape of TB and reveals AS as a key regulatory mechanism shaping immune dysfunction and recovery during infection and treatment immune.
- Open Access
- 23 December 2024
- Published by Elsevier in Journal of Infection
- Vol. 90 (1) , 106384
Hemophagocytic lymphohistiocytosis is associated with disseminated tuberculosis in patients with advanced HIV infection
- 23 December 2024
- Published by Elsevier in Journal of Infection
- Vol. 90 (1) , 106384
Open AccessHemophagocytic lymphohistiocytosis is associated with disseminated tuberculosis in patients with advanced HIV infection
- Open Access
Serum cytokine biosignatures for identification of tuberculosis among HIV-positive inpatients
Background: Serum cytokines correlate with tuberculosis (TB) progression and are predictors of TB recurrence in people living with HIV. We investigated whether serum cytokine biosignatures could diagnose TB among HIV-positive inpatients.Methods: We recruited HIV-positive inpatients with symptoms of TB and measured serum levels of inflammation biomarkers including IL-2, IL-4, IL-6, IL-10, tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ). We then built and tested our TB prediction model.Results: 236 HIV-positive inpatients were enrolled in the first cohort and all the inflammation biomarkers were significantly higher in participants with microbiologically confirmed TB than those without TB. A binary support vector machine (SVM) model was built, incorporating the data of four biomarkers (IL-6, IL-10, TNF-α and IFN-γ). Efficacy of the SVM model was assessed in training (n=189) and validation (n=47) sets with area under the curve (AUC) of 0.92 (95% CI 0.88 to 0.96) and 0.85 (95% CI 0.72 to 0.97), respectively. In an independent test set (n=110), the SVM model yielded an AUC of 0.85 (95% CI 0.76 to 0.94) with 78% (95% CI 68% to 87%) specificity and 85% (95% CI 66% to 96%) sensitivity. Moreover, the SVM model outperformed interferon-gamma release assay (IGRA) among advanced HIV-positive inpatients irrespective of CD4+T-cell counts, which may be an alternative approach for identifyingMycobacterium tuberculosisinfection among HIV-positive inpatients with negative IGRA.Conclusions: The four-cytokine biosignature model successfully identified TB among HIV-positive inpatients. This diagnostic model may be an alternative approach to diagnose TB in advanced HIV-positive inpatients with low CD4+T-cell counts.
Open AccessSerum cytokine biosignatures for identification of tuberculosis among HIV-positive inpatients
Background: Serum cytokines correlate with tuberculosis (TB) progression and are predictors of TB recurrence in people living with HIV. We investigated whether serum cytokine biosignatures could diagnose TB among HIV-positive inpatients.Methods: We recruited HIV-positive inpatients with symptoms of TB and measured serum levels of inflammation biomarkers including IL-2, IL-4, IL-6, IL-10, tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ). We then built and tested our TB prediction model.Results: 236 HIV-positive inpatients were enrolled in the first cohort and all the inflammation biomarkers were significantly higher in participants with microbiologically confirmed TB than those without TB. A binary support vector machine (SVM) model was built, incorporating the data of four biomarkers (IL-6, IL-10, TNF-α and IFN-γ). Efficacy of the SVM model was assessed in training (n=189) and validation (n=47) sets with area under the curve (AUC) of 0.92 (95% CI 0.88 to 0.96) and 0.85 (95% CI 0.72 to 0.97), respectively. In an independent test set (n=110), the SVM model yielded an AUC of 0.85 (95% CI 0.76 to 0.94) with 78% (95% CI 68% to 87%) specificity and 85% (95% CI 66% to 96%) sensitivity. Moreover, the SVM model outperformed interferon-gamma release assay (IGRA) among advanced HIV-positive inpatients irrespective of CD4+T-cell counts, which may be an alternative approach for identifyingMycobacterium tuberculosisinfection among HIV-positive inpatients with negative IGRA.Conclusions: The four-cytokine biosignature model successfully identified TB among HIV-positive inpatients. This diagnostic model may be an alternative approach to diagnose TB in advanced HIV-positive inpatients with low CD4+T-cell counts.
- Top Cited PapersOpen Access
- 17 April 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (8)
Mycobacterium tuberculosis hijacks host TRIM21- and NCOA4-dependent ferritinophagy to enhance intracellular growth
Ferritin, a key regulator of iron homeostasis in macrophages, has been reported to confer host defenses against Mycobacterium tuberculosis (Mtb) infection. Nuclear receptor coactivator 4 (NCOA4) was recently identified as a cargo receptor in ferritin degradation. Here, we show that Mtb infection enhanced NCOA4-mediated ferritin degradation in macrophages, which in turn increased the bioavailability of iron to intracellular Mtb and therefore promoted bacterial growth. Of clinical relevance, the upregulation of FTH1 in macrophages was associated with tuberculosis (TB) disease progression in humans. Mechanistically, Mtb infection enhanced NCOA4-mediated ferritin degradation through p38/AKT1- and TRIM21-mediated proteasomal degradation of HERC2, an E3 ligase of NCOA4. Finally, we confirmed that NCOA4 deficiency in myeloid cells expedites the clearance of Mtb infection in a murine model. Together, our findings revealed a strategy by which Mtb hijacks host ferritin metabolism for its own intracellular survival. Therefore, this represents a potential target for host-directed therapy against tuberculosis.
- 17 April 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (8)
Top Cited PapersOpen AccessMycobacterium tuberculosis hijacks host TRIM21- and NCOA4-dependent ferritinophagy to enhance intracellular growth
Ferritin, a key regulator of iron homeostasis in macrophages, has been reported to confer host defenses against Mycobacterium tuberculosis (Mtb) infection. Nuclear receptor coactivator 4 (NCOA4) was recently identified as a cargo receptor in ferritin degradation. Here, we show that Mtb infection enhanced NCOA4-mediated ferritin degradation in macrophages, which in turn increased the bioavailability of iron to intracellular Mtb and therefore promoted bacterial growth. Of clinical relevance, the upregulation of FTH1 in macrophages was associated with tuberculosis (TB) disease progression in humans. Mechanistically, Mtb infection enhanced NCOA4-mediated ferritin degradation through p38/AKT1- and TRIM21-mediated proteasomal degradation of HERC2, an E3 ligase of NCOA4. Finally, we confirmed that NCOA4 deficiency in myeloid cells expedites the clearance of Mtb infection in a murine model. Together, our findings revealed a strategy by which Mtb hijacks host ferritin metabolism for its own intracellular survival. Therefore, this represents a potential target for host-directed therapy against tuberculosis.
- 11 April 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (6) , e156-e157
Low levels of humoral response to monkeypox virus-specific antigens in healthy individuals
- 11 April 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (6) , e156-e157
Low levels of humoral response to monkeypox virus-specific antigens in healthy individuals
- Open Access
- 27 January 2021
- Published by Springer Nature in Research Square
Predictive value of a Five-Biomarker Signature to Diagnose Active Pulmonary Tuberculosis Patients
Background: To improve the diagnosis accuracy of active pulmonary tuberculosis (TB) from pneumonia (PN) in low income and inadequate facilities areas is one of the biggest problems facing public health today. Most TB patients are difficult to diagnose, especially those who are acid-fast bacillus smear-negative (AFB-) but IGRA®.TB test positive (IGRA+). Thus, we aim to develop a low-cost and rapid risk model for the diagnosis of TB patients with AFB- IGRA+ TB from PN.Methods: We retrospectively analyzed 41 laboratory variables of 204 AFB- IGRA+ TB and 156 PN participants. Candidate variables were identified by t-statistic test and univariate logistic model. The logistic regression analysis was used to construct the multivariate risk model and nomogram with internal and external validation.Results: There were differential correlations between variable pairs in AFB- IGRA+ TB and PN. We found several significant variables in TB compared with PN. Among them, uric acid (UA) was up-elevated , acting as a protective factor with an odds ratio (OR) < 1. By integrating five variables, including Age, UA, albumin (ALB), hemoglobin (Hb) and white blood cell counts (WBC), we constructed a multivariate risk model with a concordance index (C-index) of 0.7 (95% CI: 0.61, 0.8). Nomogram showed that UA and Hb had the protection effect, while Age, WBC and ALB acted as risk factors on TB occurrence. Internal and external validation revealed a good agreement between nomogran prediction and actual observations.Conclusions: Differential correlations existed between variable pairs in AFB- IGRA+ TB and PN. An integration of five biomarkers (Age, UA, ALB, Hb and WBC) can be used to predict TB in AFB- IGRA+ clinical samples from PN.
- 27 January 2021
- Published by Springer Nature in Research Square
Open AccessPredictive value of a Five-Biomarker Signature to Diagnose Active Pulmonary Tuberculosis Patients
Background: To improve the diagnosis accuracy of active pulmonary tuberculosis (TB) from pneumonia (PN) in low income and inadequate facilities areas is one of the biggest problems facing public health today. Most TB patients are difficult to diagnose, especially those who are acid-fast bacillus smear-negative (AFB-) but IGRA®.TB test positive (IGRA+). Thus, we aim to develop a low-cost and rapid risk model for the diagnosis of TB patients with AFB- IGRA+ TB from PN.Methods: We retrospectively analyzed 41 laboratory variables of 204 AFB- IGRA+ TB and 156 PN participants. Candidate variables were identified by t-statistic test and univariate logistic model. The logistic regression analysis was used to construct the multivariate risk model and nomogram with internal and external validation.Results: There were differential correlations between variable pairs in AFB- IGRA+ TB and PN. We found several significant variables in TB compared with PN. Among them, uric acid (UA) was up-elevated , acting as a protective factor with an odds ratio (OR) < 1. By integrating five variables, including Age, UA, albumin (ALB), hemoglobin (Hb) and white blood cell counts (WBC), we constructed a multivariate risk model with a concordance index (C-index) of 0.7 (95% CI: 0.61, 0.8). Nomogram showed that UA and Hb had the protection effect, while Age, WBC and ALB acted as risk factors on TB occurrence. Internal and external validation revealed a good agreement between nomogran prediction and actual observations.Conclusions: Differential correlations existed between variable pairs in AFB- IGRA+ TB and PN. An integration of five biomarkers (Age, UA, ALB, Hb and WBC) can be used to predict TB in AFB- IGRA+ clinical samples from PN.
- Open Access
- 20 January 2021
- Published by Springer Nature in Research Square
Predictive Value of a Five-biomarker Signature to Diagnose Active Pulmonary Tuberculosis Patients
Background: To improve the diagnosis accuracy of active pulmonary tuberculosis (TB) from pneumonia (PN) in low income and inadequate facilities areas is one of the biggest problems facing public health today. Most TB patients are difficult to diagnose, especially those who are acid-fast bacillus smear-negative (AFB-) but IGRA®.TB test positive (IGRA+). Thus, we aim to develop a low-cost and rapid risk model for the diagnosis of TB patients with AFB- IGRA+ TB from PN.Methods: We retrospectively analyzed 41 laboratory variables of 204 AFB- IGRA+ TB and 156 PN participants. Candidate variables were identified by t-statistic test and univariate logistic model. The logistic regression analysis was used to construct the multivariate risk model and nomogram with internal and external validation.Results: There were differential correlations between variable pairs in AFB- IGRA+ TB and PN. We found several significant variables in TB compared with PN. Among them, uric acid (UA) was up-elevated , acting as a protective factor with an odds ratio (OR) < 1. By integrating five variables, including Age, UA, albumin (ALB), hemoglobin (Hb) and white blood cell counts (WBC), we constructed a multivariate risk model with a concordance index (C-index) of 0.7 (95% CI: 0.61, 0.8). Nomogram showed that UA and Hb had the protection effect, while Age, WBC and ALB acted as risk factors on TB occurrence. Internal and external validation revealed a good agreement between nomogran prediction and actual observations.Conclusions: Differential correlations existed between variable pairs in AFB- IGRA+ TB and PN. An integration of five biomarkers (Age, UA, ALB, Hb and WBC) can be used to predict TB in AFB- IGRA+ clinical samples from PN.
- 20 January 2021
- Published by Springer Nature in Research Square
Open AccessPredictive Value of a Five-biomarker Signature to Diagnose Active Pulmonary Tuberculosis Patients
Background: To improve the diagnosis accuracy of active pulmonary tuberculosis (TB) from pneumonia (PN) in low income and inadequate facilities areas is one of the biggest problems facing public health today. Most TB patients are difficult to diagnose, especially those who are acid-fast bacillus smear-negative (AFB-) but IGRA®.TB test positive (IGRA+). Thus, we aim to develop a low-cost and rapid risk model for the diagnosis of TB patients with AFB- IGRA+ TB from PN.Methods: We retrospectively analyzed 41 laboratory variables of 204 AFB- IGRA+ TB and 156 PN participants. Candidate variables were identified by t-statistic test and univariate logistic model. The logistic regression analysis was used to construct the multivariate risk model and nomogram with internal and external validation.Results: There were differential correlations between variable pairs in AFB- IGRA+ TB and PN. We found several significant variables in TB compared with PN. Among them, uric acid (UA) was up-elevated , acting as a protective factor with an odds ratio (OR) < 1. By integrating five variables, including Age, UA, albumin (ALB), hemoglobin (Hb) and white blood cell counts (WBC), we constructed a multivariate risk model with a concordance index (C-index) of 0.7 (95% CI: 0.61, 0.8). Nomogram showed that UA and Hb had the protection effect, while Age, WBC and ALB acted as risk factors on TB occurrence. Internal and external validation revealed a good agreement between nomogran prediction and actual observations.Conclusions: Differential correlations existed between variable pairs in AFB- IGRA+ TB and PN. An integration of five biomarkers (Age, UA, ALB, Hb and WBC) can be used to predict TB in AFB- IGRA+ clinical samples from PN.
- Open Access
- 29 August 2013
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 25 (10) , 589-599
Removal of myeloid cytokines from the cellular environment enhances T-cell development in vitro
The majority of T-cell development occurs in the thymus. Thymic epithelial cells are specialized cells that express NOTCH ligands and secrete specific cytokines required for normal T-cell lymphopoiesis. It has been demonstrated that OP9 cells derived from macrophage colony-stimulating factor (M-CSF)-deficient mice can support T-cell development when transduced with a NOTCH ligand, Delta-like 1 (Dll1). In this report, we have tested CSF-deficient mouse fibroblasts transduced with Dll1 for their ability to support T-cell differentiation. The data provided here demonstrate that CSF-deficient fibroblasts expressing DLL1 can support T-cell development. Indeed, co-cultures with these fibroblasts produced more T-cell progenitors compared with OP9-DL1 cultures. Addition of myeloid cytokines to OP9-DL1 co-cultures significantly inhibited T-cell development while CSF-deficient DLL1+ fibroblasts retained partial T-cell differentiation. Taken together, these data imply that their lack of myeloid cytokines allows DLL1+ fibroblasts to more efficiently generate T-cells. Development of this fibroblast system suggests that there is potential for generating human T-cell precursors via co-culture with human fibroblasts expressing DLL1 or DLL4. These T-cell precursors could be used for treating immunodeficient patients.
- 29 August 2013
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 25 (10) , 589-599
Open AccessRemoval of myeloid cytokines from the cellular environment enhances T-cell development in vitro
The majority of T-cell development occurs in the thymus. Thymic epithelial cells are specialized cells that express NOTCH ligands and secrete specific cytokines required for normal T-cell lymphopoiesis. It has been demonstrated that OP9 cells derived from macrophage colony-stimulating factor (M-CSF)-deficient mice can support T-cell development when transduced with a NOTCH ligand, Delta-like 1 (Dll1). In this report, we have tested CSF-deficient mouse fibroblasts transduced with Dll1 for their ability to support T-cell differentiation. The data provided here demonstrate that CSF-deficient fibroblasts expressing DLL1 can support T-cell development. Indeed, co-cultures with these fibroblasts produced more T-cell progenitors compared with OP9-DL1 cultures. Addition of myeloid cytokines to OP9-DL1 co-cultures significantly inhibited T-cell development while CSF-deficient DLL1+ fibroblasts retained partial T-cell differentiation. Taken together, these data imply that their lack of myeloid cytokines allows DLL1+ fibroblasts to more efficiently generate T-cells. Development of this fibroblast system suggests that there is potential for generating human T-cell precursors via co-culture with human fibroblasts expressing DLL1 or DLL4. These T-cell precursors could be used for treating immunodeficient patients.